ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

MINNEAPOLIS--(BUSINESS WIRE)--HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in ...

An analysis of the 2025 AHA/ACC hypertension guidelines found that under the new guidelines, about 11% of adults ages 65 to 79 with stage I hypertension would no longer qualify for blood pressure ...

Endometrial cancer (EC) is a hormonally driven malignancy with a strikingly uneven global distribution, interestingly occurring far more frequently in developed countries. Central to its pathogenesis ...

Emerging treatments for classic congenital adrenal hyperplasia (CAH) may make it easier to manage the condition, which occurs when you don’t have enough of the enzyme you need to make the hormones ...

1 Medical Department, Kobe Detention Center, Ministry of Justice, Kobe, Japan. 2 Department of Obstetrics and Gynecology, National Hospital Organization Kobe Medical Center, Kobe, Japan. 3 Kakogawa ...

Patients with endometrial hyperplasia or benign uterine pathology had a 66% reduced risk of developing endometrial cancer when treated with progestins and a GLP-1 compared to patients treated with ...

Among women with endometrial hyperplasia or benign uterine pathology, the addition of a GLP-1 receptor agonist (RA) to progestin therapy was associated with a two-thirds lower risk for endometrial ...

Combining GLP-1 agonists with progestins lowered endometrial cancer risk by 66% compared to progestins alone. The GLP-1 agonist/progestin combination outperformed metformin/progestins in reducing ...

About The Study: In this cohort study of women with benign uterine pathology or endometrial hyperplasia, combined glucagon-like peptide-1 receptor agonist (GLP-1RA) and progestin was associated with ...

Twenty-two percent of U.S. doctors prescribing initial treatment for children with a new diagnosis of anxiety or depression during a recent six-year period chose medications that are not federally ...